Infrafrontier
INFRAFRONTIER is the European Research Infrastructure for Modelling Human Diseases, contributing to human health by advancing disease prevention and therapies through appropriate models. It is a consortium of over 20 biomedical research institutes across 15 countries, focusing on understanding mammalian gene function and modeling human diseases.
Industries
Nr. of Employees
small (1-50)
Products
PRIM-TECH3R project (standardized in vitro models from mouse cells)
Horizon-INFRA-TECH project to develop reliable, standardized complex in vitro models using mouse cells to support preclinical studies and reduce animal use according to 3R principles.
INFRAPLUS project (capacity expansion and alternative models)
Horizon-INFRA-DEV project to expand disease modelling capacity, refine services to reduce animal usage, develop alternative cellular models and optimise resource use.
Mouse and rat models broad and specialised phenotyping
Broad and specialised phenotyping services for mouse and rat models.
B6.129X1-Thtm1(cre)Te/Kieg
Mouse strain archived by EMMA and available for request as frozen embryos or via rederivation services.
B6.129X1/SvJ-Sufutm1Rto
Mouse strain archived by EMMA and available for request as frozen embryos or via rederivation services.
Mouse Models for Modelling Human Diseases
Custom mouse model generation service utilizing CRISPR/Cas9 mutagenesis technologies to create bespoke mouse models based on researcher needs, covering the production of a single F1 genome-edited mouse line.
PRIM-TECH3R project (standardized in vitro models from mouse cells)
Horizon-INFRA-TECH project to develop reliable, standardized complex in vitro models using mouse cells to support preclinical studies and reduce animal use according to 3R principles.
INFRAPLUS project (capacity expansion and alternative models)
Horizon-INFRA-DEV project to expand disease modelling capacity, refine services to reduce animal usage, develop alternative cellular models and optimise resource use.
Mouse and rat models broad and specialised phenotyping
Broad and specialised phenotyping services for mouse and rat models.
B6.129X1-Thtm1(cre)Te/Kieg
Mouse strain archived by EMMA and available for request as frozen embryos or via rederivation services.
B6.129X1/SvJ-Sufutm1Rto
Mouse strain archived by EMMA and available for request as frozen embryos or via rederivation services.
Mouse Models for Modelling Human Diseases
Custom mouse model generation service utilizing CRISPR/Cas9 mutagenesis technologies to create bespoke mouse models based on researcher needs, covering the production of a single F1 genome-edited mouse line.
Services
Collection, archiving and distribution of mouse and rat mutant strains through a central repository and catalog service.
Germ-free derivation of user-provided mouse strains to produce animals suitable for gnotobiotic and microbiome research.
Generation of custom rodent mutant strains using contemporary genome-editing technologies provided by specialized laboratories.
Provision of systematic phenotyping workflows for characterizing mouse models, linked to large-scale phenotyping consortia.
Coordination and delivery of transnational research services through open calls to support development pipelines such as oncology.
Online searchable listings of strains, downloadable strain details and related experimental protocols such as cryopreservation methods.
Collection, archiving and distribution of mouse and rat mutant strains through a central repository and catalog service.
Germ-free derivation of user-provided mouse strains to produce animals suitable for gnotobiotic and microbiome research.
Generation of custom rodent mutant strains using contemporary genome-editing technologies provided by specialized laboratories.
Provision of systematic phenotyping workflows for characterizing mouse models, linked to large-scale phenotyping consortia.
Coordination and delivery of transnational research services through open calls to support development pipelines such as oncology.
Online searchable listings of strains, downloadable strain details and related experimental protocols such as cryopreservation methods.
Expertise Areas
- Disease modelling with rodent models
- Biobanking and genetic resource management
- Rodent genome engineering and custom model generation
- Systematic phenotyping and high-throughput analysis
Key Technologies
- Cryopreservation and long-term storage
- Gnotobiotic/germ-free derivation methods
- Genome-editing for rodent model generation
- Systematic/high-throughput phenotyping pipelines
News & Updates
On-site event scheduled for 05 - 09 July 2025 in Istanbul, Turkey, organized by INFRAFRONTIER, INSTRUCT, EU-OPENSCREEN & Euro-BioImaging.
An on-site training event scheduled for 15 July 2025 at MRC Harwell, Oxfordshire, UK.
A hybrid event scheduled for 02 - 03 September 2025 in Helsinki, Finland, organized by Leadership of COST Action TEATIME.
Julia Fernández showcased INFRAFRONTIER’s contribution to the research community at the ISCIII event, highlighting its extensive mouse strain collection, valuable services, and impact on disease research.
INFRAFRONTIER hosted a dedicated session at FELASA 2025 in Athens, sharing insights on 3Rs and animal welfare in disease modeling.
Johannes Beckers has been appointed as Scientific Director, succeeding Martin Hrabě de Angelis after over 20 years of leadership.
On-site event scheduled for 05 - 09 July 2025 in Istanbul, Turkey, organized by INFRAFRONTIER, INSTRUCT, EU-OPENSCREEN & Euro-BioImaging.
An on-site training event scheduled for 15 July 2025 at MRC Harwell, Oxfordshire, UK.
A hybrid event scheduled for 02 - 03 September 2025 in Helsinki, Finland, organized by Leadership of COST Action TEATIME.
Julia Fernández showcased INFRAFRONTIER’s contribution to the research community at the ISCIII event, highlighting its extensive mouse strain collection, valuable services, and impact on disease research.
INFRAFRONTIER hosted a dedicated session at FELASA 2025 in Athens, sharing insights on 3Rs and animal welfare in disease modeling.
Johannes Beckers has been appointed as Scientific Director, succeeding Martin Hrabě de Angelis after over 20 years of leadership.